Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the ...

Strong private equity investment and strategic M&A in 2024, and a shift toward clinical-stage companies and asset-driven ...

Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of ...

Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering improved patient comfort and ...

Experts at Crowe Life Sciences offer tips for effectively managing risk associated with third parties such as clinics, retail ...

A substantial share of biopharmaceutical drug launches (>50%) fail to meet their projected analyst forecasts (see also Simon-Kucher Biotech industry study 2019). With considerable investment going ...